MediciNova (NASDAQ:MNOV) Rating Increased to Hold at Zacks Research

MediciNova (NASDAQ:MNOV) was upgraded by stock analysts at Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on the company. Lucid Cap Mkts upgraded MediciNova to a “strong-buy” rating in a report on Monday, January 5th. HC Wainwright began coverage on MediciNova in a report on Monday. They set a “buy” rating and a $10.00 target price for the company. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of MediciNova in a research report on Friday, January 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediciNova in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $8.00.

MediciNova Stock Down 4.1%

Shares of NASDAQ MNOV opened at $1.41 on Tuesday. The company’s 50-day simple moving average is $1.54 and its 200-day simple moving average is $1.42. MediciNova has a 52-week low of $1.13 and a 52-week high of $1.96. The firm has a market cap of $69.40 million, a price-to-earnings ratio of -5.87 and a beta of 0.58.

MediciNova (NASDAQ:MNOV) last released its earnings results on Friday, February 20th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. The company had revenue of $0.15 million for the quarter. Equities research analysts anticipate that MediciNova will post -0.24 EPS for the current fiscal year.

Institutional Trading of MediciNova

Several large investors have recently bought and sold shares of MNOV. StoneX Group Inc. acquired a new stake in MediciNova in the 4th quarter valued at about $25,000. Goldman Sachs Group Inc. acquired a new position in shares of MediciNova during the 4th quarter worth approximately $35,000. Citadel Advisors LLC acquired a new position in shares of MediciNova during the 3rd quarter worth approximately $92,000. Jane Street Group LLC purchased a new stake in shares of MediciNova in the fourth quarter valued at approximately $214,000. Finally, State Street Corp grew its position in shares of MediciNova by 10.9% in the fourth quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 19,100 shares in the last quarter. Hedge funds and other institutional investors own 9.90% of the company’s stock.

Key Stories Impacting MediciNova

Here are the key news stories impacting MediciNova this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $10 price target, a material bullish endorsement for a small-cap biotech that can attract new investor attention and trading interest. HC Wainwright Initiates Coverage on MediciNova (NASDAQ:MNOV)
• Positive Sentiment: The analyst model projects multi-year upside: HC Wainwright’s forecasts show MediciNova moving from near-term losses to profitability (projected EPS of $0.29 in FY2028, $1.90 in FY2029 and $3.02 in FY2030). That long-term earnings runway supports the high $10 target and could justify speculative buying by growth-oriented investors. HC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendation
• Neutral Sentiment: HC Wainwright’s near-term quarterly estimates remain negative (Q1–Q3 2026: ~$0.06 loss per share; Q4 2026: ~$0.08 loss), and FY2026 is modeled at a loss — meaning any upside depends on successful execution and clinical/commercial progress rather than immediate earnings improvement.
• Negative Sentiment: Despite the bullish initiation, the stock is down today—likely reflecting that the market is weighing near-term negative EPS, small market cap/liquidity and skepticism over execution risk before the multi-year upside can be realized. Volume is modest and technicals (50/200-day moving averages near the current price) suggest limited conviction so far.

About MediciNova

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.